ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last781 to 800 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Intervention Arm vs Placebo Arm: Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy42 of 5,956

30 of 5,946

0.2 points

-0.1 to 0.5

11,902NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Intervention Arm vs Placebo Arm: deaths from any cause9 of 5,943

12 of 5,936

-0.1 points

-0.2 to 0.1

11,879NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Intervention Arm vs Placebo Arm: serious adverse events832 of 5,943

857 of 5,936

-0.4 points

-1.7 to 0.8

11,879NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Intervention Arm vs Placebo Arm: Maternal Outcome 1 - Incidence of Vaginal Bleeding214 of 5,933

246 of 5,940

-0.5 points

-1.2 to 0.2

11,873NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Cases vs Controls: Number of Female Participants Aged 18-44 Using Oestrogen Contraceptive With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person31 of 4,917

34 of 6,925

0.1 points

-0.1 to 0.4

11,842NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Intervention Arm vs Placebo Arm: Maternal Outcome 3 - Incidence of Postpartum Hemorrhage54 of 5,928

43 of 5,907

0.2 points

-0.1 to 0.5

11,835NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Pre-intervention vs Post-intervention: Cumulative Incidence of ART Initiation 14 Days After Clinical Eligibility in Treatment Eligible HIV-infected Patients2,585 of 7,066

3,753 of 4,747

-42.5 points

-44.1 to -40.8

11,813NCT01810289

The "START" (a Streamlined ART Initiation Strategy) Study

M-001 vs Saline: Number of Participants With Influenza-like Illness Symptoms1,231 of 5,864

1,266 of 5,905

-0.4 points

-1.9 to 1.0

11,769NCT03450915

A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine

M-001 vs Saline: Number of Participants With Culture-confirmed Influenza Incidence111 of 5,864

96 of 5,905

0.3 points

-0.2 to 0.7

11,769NCT03450915

A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine

Anesthesia Control Tower Monitoring vs Standard of Care Arm: Antibiotic Redosing5,629 of 5,919

5,520 of 5,811

0.1 points

-0.7 to 0.9

11,730NCT03923699

Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety

MF/F MDI BID vs MF MDI BID: deaths from any cause5 of 5,868

4 of 5,861

0.0 points

-0.1 to 0.1

11,729NCT01471340

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

MF/F MDI BID vs MF MDI BID: serious adverse events136 of 5,868

137 of 5,861

-0.0 points

-0.6 to 0.5

11,729NCT01471340

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

Symbicort vs Budesonide: Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization)43 of 5,846

40 of 5,847

0.1 points

-0.3 to 0.4

11,693NCT01444430

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Symbicort vs Budesonide: Number of Participants Experiencing Discontinuation of Investigational Product Due to a Protocol Defined Asthma Exacerbation53 of 5,846

71 of 5,847

-0.3 points

-0.7 to 0.1

11,693NCT01444430

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Symbicort vs Budesonide: Number of Participants Experiencing an Event Included in the Definition of Asthma Exacerbation539 of 5,846

633 of 5,847

-1.6 points

-2.7 to -0.5

11,693NCT01444430

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Symbicort vs Budesonide: serious adverse events125 of 5,846

123 of 5,847

0.0 points

-0.5 to 0.6

11,693NCT01444430

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing at Least One Asthma Exacerbation480 of 5,834

597 of 5,845

-2.0 points

-3.0 to -0.9

11,679NCT01475721

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation66 of 5,834

84 of 5,845

-0.3 points

-0.7 to 0.1

11,679NCT01475721

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)34 of 5,834

33 of 5,845

0.0 points

-0.3 to 0.3

11,679NCT01475721

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): serious adverse events134 of 5,834

125 of 5,845

0.2 points

-0.4 to 0.7

11,679NCT01475721

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=40

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02409680-e7b475cd",
        "title": "Intervention Arm vs Placebo Arm: Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy",
        "summary": "42 of 5956 against 30 of 5946; risk difference 0.2 points, 95% interval -0.1 to 0.5; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
        "record": "/library/comparisons/NCT02409680-e7b475cd",
        "nct_id": "NCT02409680",
        "kind": "outcome",
        "participants": 11902,
        "risk_difference": {
          "value": 0.002006303880661345,
          "lower": -0.0008157526556614907,
          "upper": 0.0048971215951896865
        },
        "group_1": "42 of 5,956",
        "group_2": "30 of 5,946",
        "difference": "0.2 points",
        "interval": "-0.1 to 0.5",
        "trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
      },
      {
        "id": "NCT02409680-deaths",
        "title": "Intervention Arm vs Placebo Arm: deaths from any cause",
        "summary": "9 of 5943 against 12 of 5936; risk difference -0.1 points, 95% interval -0.2 to 0.1; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
        "record": "/library/comparisons/NCT02409680-deaths",
        "nct_id": "NCT02409680",
        "kind": "deaths",
        "participants": 11879,
        "risk_difference": {
          "value": -0.0005071766689207853,
          "lower": -0.002177909665862456,
          "upper": 0.0011056837322531042
        },
        "group_1": "9 of 5,943",
        "group_2": "12 of 5,936",
        "difference": "-0.1 points",
        "interval": "-0.2 to 0.1",
        "trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=41",
  "request_id": "w4Kl3vsnZ1ftX8ts"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?